Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5020-5026

  Wei, Shuang ^a   Kryczek, Ilona ^a,b   Zou, Linhua ^a   Daniel, Ben ^a   Cheng, Pui ^a   Mottram, Peter ^a   Curiel, Tyler ^a   Lange, Andrzej ^b   Zou, Weiping ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; TUMOR ANTIGEN;

ARTICLE; ASCITES TUMOR; BONE MARROW CELL; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MACROPHAGE; OVARY CARCINOMA; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL MOVEMENT; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; MYELOID CELLS; OVARIAN NEOPLASMS; PLASMA CELLS; RECEPTORS, CHEMOKINE;

EID: 20444485236     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4043     Document Type: Article

References (43)

1. Prevost-Blondel A, Zimmermann C, Stemmer C, et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998;161:2187-94.
2. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
3. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
4. Salio M, Shepherd D, Dunbar PR, et al. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with non-professional APC. J Immunol 2001;167:1188-97.
5. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-52.
6. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997;9:702-8.
7. Maeurer MJ, Storkus WJ, Kirkwood JM, et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996;6:11-24.
8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
9. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
10. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535-8.
11. Beatty P, Hanisch FG, Stolz DB, et al. Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients. Clin Cancer Res 2001;7:781-7s.
12. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-84.
13. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
14. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704.
15. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:4433-42.
16. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;21:21.
17. Zou W, Borvak J, Marches F, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J Immunol 2000;165:4388-96.
18. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
19. Bieche I, Parfait B, Laurendeau I, et al. Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene 2001;20:8109-15.
20. Zou W, Borvak J, Wei S, et al. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol 2001;31:3833-9.
21. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
22. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
23. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
24. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
25. Erratum in: Nat Med 1996;2:1267.
26. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-26.
27. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-22.
28. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
29. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
30. Campbell JJ, Murphy KE, Kunkel EJ, et al. CCR7 expression and memory T cell diversity in humans. J Immunol 2001;166:877-84.
31. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-85.
32. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004;10:900-1.
33. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and 1LT4. Nat Immunol 2002;3:237-43.
34. Cosmi L, Liotta F, Lazzeri E, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003;102:4107-14.
35. Rifa'i M, Kawamoto Y, Nakashima I, et al. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-34.
36. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
37. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
38. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004;5:7-10.
39. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
40. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8.
41. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
42. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
43. Schreiber H, Wu TH, Nachman J. et al. Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.